The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Open accessAbstract
Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH and VL). The proper orientation of these domains is mediated by their hydrophobic interface and is stabilized by their linkage to disulfide-linked constant domains (CH1 and CL). VH and VL domains can be fused via a genetic linker into a single chain variable fragment (scFv). scFv modules in turn can be fused to one another, e.g. to generate a bispecific T cell engager (BiTE), or they can be fused in various orientations to antibody hinge and Fc domains to generate bi- and multispecific antibodies. However, the inherent hydrophobic interaction of VH and VL domains limits the stability and solubility of engineered antibodies, often causing aggregation and/or mispairing of V-domains. Nanobodies (15 kDa) and nanobody-based human heavy chain antibodies (75 kDa) can overcome these limitations. Camelids naturally produce antibodies composed only of heavy chains in which the target recognition module is composed of a single variable domain (VHH or nanobody). Advantageous features of nanobodies include their small size, high solubility, high stability, and excellent tissue penetration in vivo. Nanobodies can readily be linked genetically to Fc-domains, other nanobodies, peptide tags, or toxins and can be conjugated chemically at a specific site to drugs, radionuclides, photosensitizers, and nanoparticles. These properties make them particularly suited for specific and efficient targeting of tumors in vivo. Chimeric nanobody-heavy chain antibodies combine advantageous features of nanobodies and human Fc domains in about half the size of a conventional antibody. In this review, we discuss recent developments and perspectives for applications of nanobodies and nanobody-based human heavy chain antibodies as anti-tumor therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The accumulated methodology of computational antibody protocols could potentially be applied to novel antibody formats with intrinsically better biophysical properties, such as nanobodies [27].”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [27]
In the citing paper
“Single domain antibodies have attracted attention because of their smaller size and better biophysical properties with respect to antibodies (higher stability and lower suspected immunogenicity) [27].”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [27]
In the citing paper
“One of the most promising is the H chain only antibody, or nanobody that are naturally occurring in camelids (llamas, alpacas and camels) [27] and sharks [228, 229] (reviewed by Muyldermans [230] and Bannas et al. [27]).”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,265
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2014) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,369
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 961
‘Knobs-into-holes’ engineering of antibody C H 3 domains for heavy chain heterodimerization
Ridgway, J. B., Presta, L. G., & Carter, P. M. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.7.617 · Cited by 816
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743
A minimal peptide substrate in biotin holoenzyme synthetase‐catalyzed biotinylation
Beckett, D., Kovaleva, E. G., & Schatz, P. J. (1999) · Protein Science · doi:10.1110/ps.8.4.921 · Cited by 727
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Hovinga, J. A. K., Cataland, S. R., Knöbl, P., Wu, H. M., Artoni, A., Westwood, J., Taleghani, M. M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 667
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 603
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 572
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 553
Sortagging: a versatile method for protein labeling
Popp, M. W., Antos, J. M., Grotenbreg, G. M., Spooner, E., & Ploegh, H. L. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.31 · Cited by 542
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juárez‐Moreno, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 529
Muyldermans, S., Atarhouch, T., Saldanha, J. W., Barbosa, J. A. R. G., & HAMERS, R. (1994) · Protein Engineering Design and Selection · doi:10.1093/protein/7.9.1129 · Cited by 495
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 476
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 459
Nanobody-based products as research and diagnostic tools
Meyer, T. D., Muyldermans, S., & Depicker, A. G. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.03.001 · Cited by 450
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 447
Site-Specific Biotinylation of Purified Proteins Using BirA
Fairhead, M., & Howarth, M. R. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2272-7_12 · Cited by 419
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez‐Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., BAETSELIER, P. D., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 383
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., Taeye, S. D., Verkleij, A. J., Revets, H., de Haard, H., & Henegouwen, P. M. P. V. B. E. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 348
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Tijink, B. M., Laeremans, T., Budde, M., van Walsum, M., Dreier, T., de Haard, H., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 310
Immunotoxins for targeted cancer therapy
Kreitman, R. J. (2006) · The AAPS Journal · doi:10.1208/aapsj080363 · Cited by 308
Coppieters, K. T., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., de Wiele, C. V., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303
Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 301
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 299
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 297
Current progress in innovative engineered antibodies
Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 296
Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., Bouwens, L., Lahoutte, T., BAETSELIER, P. D., Raes, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2994 · Cited by 292
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.001 · Cited by 289
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & Henegouwen, P. M. P. V. B. E. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Antibody constructs in cancer therapy
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2006) · Cancer · doi:10.1002/cncr.22402 · Cited by 280
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M. M., Dorresteijn, B., Oliveira, S., & Henegouwen, P. M. P. V. B. E. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 273
Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
Schmitz, K. R., Bagchi, A., Roovers, R. C., Henegouwen, P. M. P. V. B. E., & Ferguson, K. M. (2013) · Structure · doi:10.1016/j.str.2013.05.008 · Cited by 262
Efficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Gh., G. H., Gobert, M., Conrath, K., Muyldermans, S., BAETSELIER, P. D., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260
Nanobodies as novel agents for cancer therapy
Revets, H., BAETSELIER, P. D., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Rashidian, M., Ingram, J. R., Dougan, M. L., Dongre, A., Whang, K. A., Gall, C. M. L., Cragnolini, J. J., Bierie, B., Gostissa, M., Gorman, J. R., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161950 · Cited by 253
Jähnichen, S., Blanchetot, C., Maussang, D., González-Pajuelo, M., Chow, K. Y. C., Bosch, L., Vrieze, S. D., Serruys, B., Ulrichts, H., Vandevelde, W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012865107 · Cited by 251
Pleiner, T., Bates, M., Trakhanov, S. D., Lee, C., Schliep, J. E., Chug, H., Böhning, M., Stark, H., Urlaub, H., & Görlich, D. (2015) · eLife · doi:10.7554/elife.11349 · Cited by 246
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
Dumoulin, M., Last, A. M., Desmyter, A., Decanniere, K., Canet, D., Larsson, G., Spencer, A. G., Archer, D. B., Sasse, J., Muyldermans, S., et al. (2003) · Nature · doi:10.1038/nature01870 · Cited by 243
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 231
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer
Audenhove, I. V., & Gettemans, J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.028 · Cited by 228
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
D’Huyvetter, M., Vincke, C., Xavier, C., Aerts, A., Impens, N. R. E. N., Baatout, S., Raeve, H. D., Muyldermans, S., Caveliers, V., Devoogdt, N., et al. (2014) · Theranostics · doi:10.7150/thno.8156 · Cited by 226
Gainkam, L. O. T., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., BAETSELIER, P. D., & Lahoutte, T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048538 · Cited by 222
Noninvasive imaging of immune responses
Rashidian, M., Keliher, E. J., Bilate, A. M. B., Duarte, J. N., Wojtkiewicz, G. R., Jacobsen, J. T., Cragnolini, J., Swee, L. K., Victora, G. D., Weissleder, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502609112 · Cited by 218
Targeting tumors with nanobodies for cancer imaging and therapy
Oliveira, S., Heukers, R., Sornkom, J., Kok, R. J., & Henegouwen, P. M. P. V. B. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.298 · Cited by 215
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 1×
“, rat IgG2a and rat lambda on the one side and mouse IgG2b and mouse kappa on the other side, reduces mispairing of the VL and VH domains (50).”
BackgroundFormation of a bispecific antibody by the use of leucine zippers
Kostelny, S. A., Cole, M. S., & Tso, J. Y. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1547 · Cited by 211
SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression
Huang, L., Gainkam, L. O. T., Caveliers, V., Vanhove, C., Keyaerts, M., BAETSELIER, P. D., Bossuyt, A. M., Revets, H., & Lahoutte, T. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0133-8 · Cited by 202
Oliveira, S., van Dongen, G. A. M. S., van Walsum, M., Roovers, R. C., Stam, J. C., Mali, W. P. T. M., van Diest, P. J., & Henegouwen, P. M. P. V. B. E. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
Beghein, E., & Gettemans, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00771 · Cited by 194
Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation
Danquah, W., Meyer‐Schwesinger, C., Rissiek, B., Pinto, C., Prat, A. S., Amadi, M., Iacenda, D., Knop, J., Hammel, A., Bergmann, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8463 · Cited by 191
Massa, S., Xavier, C., Vos, J. D., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500111t · Cited by 189
Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M., & Kay, N. E. (1994) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.365-372.1994 · Cited by 185
Dekempeneer, Y., Keyaerts, M., Krasniqi, A., Puttemans, J., Muyldermans, S., Lahoutte, T., D’Huyvetter, M., & Devoogdt, N. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1185412 · Cited by 175
van Driel, P. B. A. A., Boonstra, M. C., Slooter, M. D., Heukers, R., Stammes, M. A., Snoeks, T. J. A., de Bruijn, H. S., van Diest, P. J., Vahrmeijer, A. L., Henegouwen, P. M. P. V. B. E., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.014 · Cited by 168
Papadopoulos, K. P., ISAACS, R. E., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D. W., Kundamal, N., Tang, Z., Cooksey, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2712-0 · Cited by 162
Blykers, A., Schoonooghe, S., Xavier, C., D’hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G. M., Heemskerk, J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156828 · Cited by 160
Single domain antibodies: comparison of camel VH and camelised human VH domains
Riechmann, L., & Muyldermans, S. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00138-6 · Cited by 158
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., Henegouwen, P. M. P. V. B. E., Storm, G., & Roovers, R. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.020 · Cited by 149
Maussang, D., Mujić-Delić, A., Descamps, F. J., Stortelers, C., Vanlandschoot, P., van Walsum, M., Vischer, H. F., Roy, M. V., Vosjan, M. J. W. D., González-Pajuelo, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498436 · Cited by 148
Gainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O. C., Muyldermans, S., Bossuyt, A. M., & Lahoutte, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.408 · Cited by 148
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0891 · Cited by 146
The development of nanobodies for therapeutic applications.
Bockstaele, F. V., Holz, J.-B., & Revets, H. (2009) · PubMed · Cited by 144
Hmila, I., Abderrazek, R. B., Saerens, D., Benlasfar, Z., Conrath, K., Ayeb, M. E., Muyldermans, S., & Bouhaouala‐Zahar, B. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.04.011 · Cited by 140
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132
Vos, J. D., Devoogdt, N., Lahoutte, T., & Muyldermans, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.800478 · Cited by 128
Baker, J. H. E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J., & Minchinton, A. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4465 · Cited by 125
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
D’Huyvetter, M., Xavier, C., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.941803 · Cited by 124
Altıntaş, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., Henegouwen, P. M. P. V. B. E., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.007 · Cited by 121
van Schie, K. A., Wolbink, G., & Rispens, T. (2015) · mAbs · doi:10.1080/19420862.2015.1048411 · Cited by 119
Koch‐Nolte, F., Reyelt, J., Schößow, B., Schwarz, N., Scheuplein, F., Rothenburg, S., Haag, F., Alzogaray, V., Cauerhff, A., & Goldbaum, F. A. (2007) · The FASEB Journal · doi:10.1096/fj.07-8661com · Cited by 119
Albert, S., Arndt, C., Feldmann, A., Bergmann, R., Bachmann, D., Koristka, S., Ludwig, F., Ziller-Walter, P., Kegler, A., Gärtner, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1287246 · Cited by 116
Introduction to Heavy Chain Antibodies and Derived Nanobodies
Vincke, C., & Muyldermans, S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_2 · Cited by 114
Talelli, M., Rijcken, C. J. F., Oliveira, S., van der Meel, R., Henegouwen, P. M. P. V. B. E., Lammers, T., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.015 · Cited by 114
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
Liu, H., Saxena, A., Sidhu, S. S., & Wu, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 114
Immunogenicity of therapeutic recombinant immunotoxins
Mazor, R., Onda, M., & Pastan, I. H. (2016) · Immunological Reviews · doi:10.1111/imr.12390 · Cited by 110
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M. R., Kowal, C., Yang, G., Royo, A., et al. (2014) · mAbs · doi:10.4161/19420862.2014.975099 · Cited by 109
Debie, P., Quathem, J. V., Hansen, I., Bala, G., Massa, S., Devoogdt, N., Xavier, C., & Hernot, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01053 · Cited by 106
van der Meel, R., Oliveira, S., Altıntaş, I., Haselberg, R., van der Veeken, J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Schiffelers, R. M., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.027 · Cited by 105
Nardis, C. D., Hendriks, L. J. A., Poirier, E., Arvinte, T., Gros, P., Bakker, A. B. H., & de Kruif, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793497 · Cited by 105
Nanobody–photosensitizer conjugates for targeted photodynamic therapy
Heukers, R., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.007 · Cited by 100
The Human Immune Response to the OKT3 Monoclonal Antibody Is Oligoclonal
Chatenoud, L., Jonker, M., Villemain, F., Goldstein, G., & Bach, J. (1986) · Science · doi:10.1126/science.3086976 · Cited by 98
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
Lemaire, M., D’Huyvetter, M., Lahoutte, T., Valckenborgh, E. V., Menu, E., Bruyne, E. D., Kronenberger, P., Wernery, U., Muyldermans, S., Devoogdt, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.292 · Cited by 98
Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
Bartúnek, J., Barbato, E., Heyndrickx, G. R., Vanderheyden, M., Wijns, W. C., & Holz, J.-B. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9435-y · Cited by 95
Jamnani, F. R., Rahbarizadeh, F., Shokrgozar, M. A., Mahboudi, F., Ahmadvand, D., Sharifzadeh, Z., Parhamifar, L., & Moghimi, S. M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.09.029 · Cited by 93
Iqbal, U. H., Trojahn, U., Albaghdadi, H., Zhang, J., O'Connor‐McCourt, M. D., Stanimirovic, D. B., Tomanek, B., Sutherland, G. R., & Abulrob, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00742.x · Cited by 85
Behdani, M., Zeinali, S., Karimipour, M., Khanahmad, H., Schoonooghe, S., Aslemarz, A., Seyed, N., Moazzami, R., Baniahmad, F., Habibi‐Anbouhi, M., et al. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.09.002 · Cited by 85
Heukers, R., Altıntaş, I., Raghoenath, S., Zan, E. D., Pepermans, R. A., Roovers, R. C., Haselberg, R., Hennink, W. E., Schiffelers, R. M., Kok, R. J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.001 · Cited by 83
Sheng, Z., Schramm, C. A., Kong, R., Program, N. C. S., Mullikin, J. C., Mascola, J. R., Kwong, P. D., & Shapiro, L. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00537 · Cited by 78
Immuno-targeting the multifunctional CD38 using nanobody
Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Du, X., Zhang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27055 · Cited by 75
Unger, M., Eichhoff, A. M., Schumacher, L., Strysio, M., Menzel, S., Schwan, C., Alzogaray, V., Zylberman, V., Séman, M., Brandner, J. M., et al. (2015) · Scientific Reports · doi:10.1038/srep07850 · Cited by 74
Yuan, Y. J., Li, J., Zhu, X., Tang, X., Bao, Y., Sun, X., Huang, Y., Tian, F., Liu, X., & Yang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s127575 · Cited by 74
Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody
Kazemi‐Lomedasht, F., Behdani, M., Bagheri, K. P., Habibi‐Anbouhi, M., Abolhassani, M., Arezumand, R., Shahbazzadeh, D., & Mirzahoseini, H. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.010 · Cited by 70
Evazalipour, M., D’Huyvetter, M., Tehrani, B. S., Abolhassani, M., Omidfar, K., Abdoli, S., Arezumand, R., Morovvati, H., Lahoutte, T., Muyldermans, S., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1558 · Cited by 70
Sadeqzadeh, E., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., Parhamifar, L., & Moghimi, S. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.022 · Cited by 66
Jamnani, F. R., Rahbarizadeh, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., & Sharifzadeh, Z. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.004 · Cited by 62
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 60
Deng, C., Xiong, J., Gu, X., Chen, X., Wu, S., Wang, Z., Wang, D., Tu, J., & Xie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16930 · Cited by 58
Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study
Zou, T., Dembele, F., Beugnet, A., Sengmanivong, L., Trépout, S., Marco, S., de Marco, A., & Li, M. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.09.034 · Cited by 57
Bannas, P., Lenz, A., Kunick, V., Well, L., Fumey, W., Rissiek, B., Haag, F., Schmid, J., Schütze, K., Eichhoff, A. M., et al. (2015) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1637 · Cited by 55
Tang, J., Li, J., Zhu, X., Yuan, Y. J., Chen, D., Yuan, L., Gu, Z.-Y., Zhang, X., Qi, L., Gong, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8710 · Cited by 54
Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function
Aghaee‐Bakhtiari, S. H., Rahbarizadeh, F., Hasannia, S., Ahmadvand, D., Sofla, F. J. I., & Rasaee, M. J. (2009) · Hybridoma · doi:10.1089/hyb.2008.0079 · Cited by 53
Neutralizing Nanobodies Targeting Diverse Chemokines Effectively Inhibit Chemokine Function
Blanchetot, C., Verzijl, D., Mujić-Delić, A., Bosch, L., Rem, L., Leurs, R., Verrips, C. T., Saunders, M. J., de Haard, H., & Smit, M. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467969 · Cited by 52
Bannas, P., Well, L., Lenz, A., Rissiek, B., Haag, F., Schmid, J., Hochgräfe, K., Trepel, M., Adam, G., Ittrich, H., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1548 · Cited by 46
Anti‐c‐ MET Nanobody® – a new potential drug in multiple myeloma treatment
Slørdahl, T. S., Denayer, T., Moen, S. H., Standal, T., Børset, M., Ververken, C., & Rø, T. B. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12185 · Cited by 46
Khaleghi, S., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., & Pognonec, P. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1037-6 · Cited by 45
van Lith, S. A. M., van Duijnhoven, S. M. J., Navis, A. C., Leenders, W. P. J., Dolk, E., Wennink, J. W. H., van Nostrum, C. F., & van Hest, J. C. M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00638 · Cited by 44
Zhu, Y., Bassoff, N., Reinshagen, C., Bhere, D., Nowicki, M. O., Lawler, S. E., Roux, J., & Shah, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02483-9 · Cited by 44
Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody
Omidfar, K., Zanjani, F. S. A., Hagh, A. G., Azizi, M. D., Rasouli, S. J., & Kashanian, S. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2790-1 · Cited by 43
Altıntaş, I., Kok, R. J., & Schiffelers, R. M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.015 · Cited by 43
A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment
Farajpour, Z., Rahbarizadeh, F., Kazemi, B., & Ahmadvand, D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.069 · Cited by 42
Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase
Sofla, F. J. I., Rahbarizadeh, F., Ahmadvand, D., & Rasaee, M. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.015 · Cited by 40
Even-Desrumeaux, K., Fourquet, P., Secq, V., Baty, D., & Chames, P. (2012) · Molecular BioSystems · doi:10.1039/c2mb25063b · Cited by 39
Araste, F., Ebrahimizadeh, W., Rasooli, I., Rajabibazl, M., & Gargari, S. L. M. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1340-1 · Cited by 38
Lehmann, A., Wixted, J. H. F., Shapovalov, M. V., Röder, H., Dunbrack, R. L., & Robinson, M. K. (2015) · mAbs · doi:10.1080/19420862.2015.1088618 · Cited by 34
AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model
Verhelle, A., Nair, N., Everaert, I., Overbeke, W. V., Supply, L., Zwaenepoel, O., Peleman, C., Dorpe, J. V., Lahoutte, T., Devoogdt, N., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx056 · Cited by 33
Drabek, D., Janssens, R., de Boer, E., Rademaker, R., Kloess, J., Skehel, J. J., & Grosveld, F. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00619 · Cited by 31
Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell
Qasemi, M., Behdani, M., Shokrgozar, M. A., Kazemiha, V. M., Mohseni-Kuchesfahani, H., & Habibi‐Anbouhi, M. (2016) · Protein Expression and Purification · doi:10.1016/j.pep.2016.03.004 · Cited by 30
Bannas, P., Lenz, A., Kunick, V., Fumey, W., Rissiek, B., Schmid, J., Haag, F., Leingärtner, A., Trepel, M., Adam, G., et al. (2015) · Journal of Visualized Experiments · doi:10.3791/52462 · Cited by 25
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells
Mo, Z., Du, P., Wang, G., & Wang, Y. (2017) · Journal of Cancer · doi:10.7150/jca.18681 · Cited by 24
Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator
Kaczmarek, J. Z., & Skottrup, P. D. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.011 · Cited by 14
Design and screening of a chimeric survivin-specific nanobody and its anticancer activities in vitro
Zhang, N., Guo, H., Zheng, W., Wang, T., & Ma, X. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000394 · Cited by 14
Flagged first, then by citations
Cited by
Sorted by citations
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Virgilio, F. D., Sarti, A. C., Falzoni, S., Marchi, E. D., & Adinolfi, E. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 748
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 537
Metadata
- Authors
- Bannas, P., Hambach, J., & Koch-Nolte, F.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-22
- Volume
- 8
- Pages
- 1603-1603
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC5702627
- OpenAlex
- W2769445535
- Cited by
- 572
- References
- 134
- Citations by year
- 2026: 51 · 2025: 68 · 2024: 93 · 2023: 62 · 2022: 70 · 2021: 85 · 2020: 68 · 2019: 48 · 2018: 27
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Wilhelm Sander-Stiftung (2012.113.2)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- nanobodies, VHH, camelid antibodies, antibody engineering, tumor targeting, antibody aggregation, bispecific T-cell engagers, antibody-drug conjugates, radionuclide conjugation, photosensitizer conjugation, nanoparticle conjugation, cancer immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
